{
    "eid": "2-s2.0-85153933579",
    "title": "Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis",
    "cover-date": "2023-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Obstetrics and Gynecology",
            "@code": "2729",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "analyzer",
        "angiogenic factors",
        "angiogenic markers",
        "asymptomatic",
        "biomarker",
        "blood pressure",
        "chronic hypertension",
        "Doppler",
        "early",
        "false positive rate",
        "gestational hypertension",
        "late",
        "maternal vascular underperfusion",
        "mean arterial pressure",
        "model",
        "multiple of median",
        "ophthalmic artery",
        "placenta",
        "placental growth factor",
        "prediction",
        "predictive performance",
        "preeclampsia",
        "pregnancy",
        "proteinuria",
        "pulsatility index",
        "sensitivity",
        "small for gestational age",
        "soluble fms-like tyrosine kinase",
        "specificity",
        "uterine artery"
    ],
    "authors": [
        "Piya Chaemsaithong",
        "Mar\u00eda M. Gil",
        "Noppadol Chaiyasit",
        "Diana Cuenca-Gomez",
        "Walter Plasencia",
        "Valeria Rolle",
        "Liona C. Poon"
    ],
    "citedby-count": 0,
    "ref-count": 163,
    "ref-list": [
        "Placental growth factor and pre-eclampsia",
        "Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions",
        "Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1",
        "VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism",
        "Circulating angiogenic factors and the risk of preeclampsia",
        "Preeclampsia is associated with reduced serum levels of placenta growth factor",
        "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia",
        "Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award",
        "Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review",
        "Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia",
        "A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate",
        "Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia",
        "Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies",
        "Discovery of antiangiogenic factors in the pathogenesis of preeclampsia",
        "A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia",
        "Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks",
        "Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia",
        "Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia",
        "Competing risks model in early screening for preeclampsia by biophysical and biochemical markers",
        "Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation",
        "Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks\u2019 gestation",
        "Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks\u2019 gestation",
        "Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population",
        "Predictive performance of the competing risk model in screening for preeclampsia",
        "Two-stage screening for preterm preeclampsia at 11-13 weeks\u2019 gestation",
        "First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia",
        "The competing risk approach for prediction of preeclampsia",
        "A new model for screening for early-onset preeclampsia",
        "Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study",
        "Competing risks model for prediction of preeclampsia",
        "Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction",
        "First trimester preeclampsia screening and prediction",
        "Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia",
        "Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders",
        "The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia",
        "Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis",
        "Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine Kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study",
        "Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement",
        "Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: a prospective cohort study",
        "ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia",
        "The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice",
        "QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies",
        "What is GRADE? 2023",
        "Chapter 10: Analysing and Presenting Results",
        "Regression methods for meta-analysis of diagnostic test data",
        "A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations",
        "Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy",
        "metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression",
        "Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort",
        "Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks\u2019 gestation",
        "Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy",
        "Prediction of preterm pre-eclampsia at midpregnancy using a multivariable screening algorithm",
        "The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia",
        "Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry",
        "Second-trimester uterine artery Doppler, PlGF, sFlt-1, sEndoglin, and lipid-related markers for predicting preeclampsia in a high-risk population",
        "Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1/PlGF ratio before the onset of early severe preeclampsia",
        "Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor",
        "Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation",
        "Combination of uterine artery Doppler velocimetry and maternal serum placental growth factor estimation in predicting occurrence of pre-eclampsia in early second trimester pregnancy: a prospective cohort study",
        "Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?",
        "Maternal cardiac function at 19-23 weeks\u2019 gestation in prediction of pre-eclampsia",
        "Serum soluble FMS-like tyrosine kinase 1 and placental growth factor concentration as predictors of preeclampsia in high risk pregnant women",
        "Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population",
        "Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry",
        "A prospective study of placental growth factor assay as a novel biomarker in predicting early-onset preeclampsia in high-risk patients",
        "Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin",
        "Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia",
        "Screening for pre-eclampsia at 35-37 weeks\u2019 gestation",
        "Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy",
        "Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks\u2019 gestation",
        "Early prediction of preeclampsia in high-risk women",
        "Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?",
        "Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion",
        "Comparison of screening for pre-eclampsia at 31-34 weeks\u2019 gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF",
        "Angiogenic factors sFlt-1 and PlGF in preeclampsia: prediction of risk and prognosis in a high-risk obstetric population",
        "Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks\u2019 gestation",
        "Biophysical and biochemical markers at 35-37 weeks\u2019 gestation in the prediction of adverse perinatal outcome",
        "Accuracy of angiogenic biomarkers at \u2a7d20weeks\u2019 gestation in predicting the risk of pre-eclampsia: a WHO multicentre study",
        "Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks\u2019 gestation",
        "From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: comprehensive approach",
        "Risk factors for adverse maternal and perinatal outcomes in women with preeclampsia: analysis of 1396 cases",
        "Prediction of imminent preeclampsia at 35-37 weeks gestation",
        "Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies",
        "Placental growth factor as a prognostic tool in women with hypertensive disorders of pregnancy: a systematic review",
        "Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis",
        "Angiogenic factors and the risk of preeclampsia: a systematic review and meta-analysis",
        "Biomarkers and the prediction of adverse outcomes in preeclampsia: a systematic review and meta-analysis",
        "Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology",
        "Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of DGGG (S1-level, AWMF Registry No. 015/018, December 2013)",
        "Italian Advisory Board: sFlt-1/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management",
        "2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy",
        "Hypertension in pregnancy: diagnosis and management. 2019",
        "Hypertensive diseases in preganncy",
        "The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention",
        "Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study",
        "A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics)",
        "Electronic address: pubs@smfm.org. Executive summary: workshop on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine and the Preeclampsia Foundation",
        "Performance of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio of \u226585 for ruling in preeclampsia within 4 weeks",
        "Placental growth factor testing in the management of late preterm preeclampsia without severe features: a multicenter, randomized, controlled trial",
        "Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1/placental growth factor ratio \u226438: secondary analysis of the Interventional Study on Prediction of Preeclampsia/eclampsia in Women with Suspected Preeclampsia",
        "Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks\u2019 gestation",
        "Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks\u2019 gestation",
        "Pre-eclampsia part 1: current understanding of its pathophysiology",
        "The clinical heterogeneity of preeclampsia is related to both placental gene expression and placental histopathology",
        "The etiology of preeclampsia",
        "Two physiological phenotypes in preeclampsia: do they really exist?",
        "Preeclampsia has two phenotypes which require different treatment strategies",
        "Reply: preeclampsia has 2 phenotypes that require different treatment strategies",
        "Molecular subclasses of preeclampsia characterized by a longitudinal maternal proteomics study: distinct biomarkers, disease pathways and options for prevention",
        "Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood",
        "Is pre-eclampsia more than one disease?",
        "Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease",
        "Early and late preeclampsia are characterized by high cardiac output, but in the presence of fetal growth restriction, cardiac output is low: insights from a prospective study",
        "Subtypes of preeclampsia: recognition and determining clinical usefulness",
        "Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia",
        "An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array",
        "Why is placentation abnormal in preeclampsia?",
        "Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes",
        "Preeclampsia: the role of persistent endothelial cells in uteroplacental arteries",
        "Placental bed research: II. Functional and immunological investigations of the placental bed",
        "Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia",
        "Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: systematic review and meta-analysis",
        "Pre-eclampsia: pathophysiology and clinical implications",
        "Increased BMI has a linear association with late-onset preeclampsia: a population-based study",
        "Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia",
        "Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease",
        "Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia",
        "Aspirin delays the development of preeclampsia",
        "Does low-dose aspirin initiated before 11 weeks\u2019 gestation reduce the rate of preeclampsia?",
        "Prevention of preeclampsia with aspirin",
        "Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials",
        "Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis",
        "When to give aspirin to prevent preeclampsia: application of Bayesian decision theory",
        "Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study",
        "Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric\u2013Fetal Pharmacology Research Units Network\u2217. Pravastatin for the prevention of preeclampsia in high-risk pregnant women",
        "Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial",
        "Pravastatin for the prevention of adverse pregnancy outcome: preeclampsia and more?",
        "A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia",
        "Pravastatin versus placebo in pregnancies at high risk of term preeclampsia",
        "Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia",
        "Statins to prevent or treat preeclampsia: sometimes it is too late",
        "The role of statins in the prevention of preeclampsia",
        "Reply: timing of pravastatin initiation for preeclampsia prevention",
        "Eculizumab for the treatment of preeclampsia/HELLP syndrome",
        "Complement activation and thrombotic microangiopathies",
        "Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome",
        "Removal of soluble Fms-like tyrosine Kinase-1 by dextran sulfate apheresis in preeclampsia",
        "Pre-eclampsia: pathogenesis, novel diagnostics and therapies",
        "VEGF (vascular endothelial growth factor) functionalized magnetic beads in a microfluidic device to improve the angiogenic balance in preeclampsia",
        "One step closer to a cure for preeclampsia?: boosting the natural affinity of VEGF (vascular endothelial growth factor) to sFlt (soluble fms-like tyrosine kinase)-1",
        "Affinity-enhanced multimeric VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) variants for specific adsorption of sFlt-1 to restore angiogenic balance in preeclampsia",
        "Extracorporeal membrane oxygenation in pregnancy: details on novel therapies and cardiac, preeclampsia, and mood disorder complications",
        "Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks\u2019 gestation",
        "Induced labour for pre-eclampsia and gestational hypertension",
        "Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks\u2019 gestation (HYPITAT): a multicentre, open-label randomised controlled trial",
        "Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis",
        "Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial",
        "Neonatal developmental and behavioral outcomes of immediate delivery versus expectant monitoring in mild hypertensive disorders of pregnancy: 2-year outcomes of the HYPITAT-II trial",
        "Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis",
        "Delivery outcomes after induction of labor among women with hypertensive disorders of pregnancy",
        "A novel approach to joint prediction of preeclampsia and delivery timing using semicompeting risks",
        "The implications of the Fetal Medicine Foundation 35- to 36-week preeclampsia prediction competing-risk model on timing of birth"
    ],
    "affiliation": [
        {
            "affiliation-city": "Oviedo",
            "@id": "60261044",
            "affilname": "Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60261044",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Pozuelo de Alarcon",
            "@id": "60108692",
            "affilname": "Universidad Francisco de Vitoria",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60108692",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": null,
            "@id": "60024787",
            "affilname": "Prince of Wales Hospital Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024787",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "La Cuesta",
            "@id": "60013249",
            "affilname": "Hospital Universitario de Canarias",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013249",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Madrid",
            "@id": "112653262",
            "affilname": "Hospital Universitario de Torrej\u00f3n",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112653262",
            "affiliation-country": "Spain"
        }
    ],
    "funding": [
        "CIBER Epidemiology and Public Health",
        "CIBERESP",
        "Institute of Metabolism and Systems Research",
        "World Health Organization Collaborating Centre for Global Women's Health",
        "University of Birmingham",
        "Thailand Science Research and Innovation"
    ]
}